The pervasive presence of plastic in modern life isn’t simply an environmental concern; it’s increasingly a question of internal biology. For decades, we’ve tracked plastic pollution’s impact on ecosystems, but only recently have scientists begun to seriously grapple with the accumulation of micro- and nanoplastics within the human body. The question isn’t if we’re ingesting these particles – evidence confirms we are, finding them in lungs, arterial plaques, and even brain tissue – but what that accumulation means for long-term health, and what, if anything, can be done about it. This is the core challenge ARPA-H’s newly announced $144 million STOMP (Systematic Targeting Of MicroPlastics) program aims to address, and it represents a significant, if cautiously optimistic, step forward in a field currently hampered by a fundamental lack of reliable data.
The announcement from HHS Secretary Robert F. Kennedy, Jr. frames microplastics as a “growing threat,” a characterization supported by animal studies demonstrating disease development following microplastic exposure, and a growing body of correlational data in human populations. However, it’s crucial to understand what the STOMP program intends to deliver versus what headlines might suggest. It’s not a rapid deployment of a “fix” for microplastic contamination. Instead, STOMP is a foundational research initiative designed to build the very tools needed to understand the problem with scientific rigor. As ARPA-H Director Alicia Jackson, Ph.D. succinctly put it, “The field is working in the dark. STOMP is turning on the lights.” The program’s initial focus isn’t removal, but measurement and mechanistic understanding – establishing a baseline of knowledge currently lacking.
This piece references the hhs.gov report.
The core issue, as highlighted by ARPA-H Program Manager Ileana Hancu, Ph.D., is the absence of standardized, accurate measurement techniques. Existing methods yield inconsistent results across laboratories, making it difficult to compare studies or establish a clear picture of the extent of microplastic accumulation. STOMP’s first phase will therefore prioritize the development of “gold-standard” measurement methods, including a clinical test capable of quantifying an individual’s microplastic burden at scale. This isn’t merely a technical challenge; it’s a prerequisite for meaningful research. Without reliable measurement, any attempt to assess risk or develop interventions is built on shaky ground. The CDC’s role as an independent validator of these methods is a critical component, aiming to build trust and ensure data consistency across the field.
Beyond simply quantifying how much plastic is present, STOMP will also tackle the question of which plastics pose the greatest risk. Not all plastics are created equal; their chemical composition, size, and shape influence how they interact with biological systems. The program aims to develop a “risk stratification mechanism” – essentially a ranking of plastic materials based on their potential for biological harm. This prioritization is essential, given the sheer diversity of plastics in our environment and the impossibility of addressing them all simultaneously. This tiered approach acknowledges the practical reality that complete elimination of plastic exposure is unrealistic, as ARPA-H Program Manager Shannon Greene, Ph.D. noted, plastics are “in everything we touch.”
However, limitations to consider are inherent in this ambitious undertaking. Phase two, focused on removal, relies entirely on the success of phase one. The assumption that understanding the mechanisms of harm will directly translate into effective removal strategies is not guaranteed. Furthermore, the program’s focus on “vulnerable groups” – pregnant women, children, those with chronic disease, and highly exposed workers – while ethically sound, raises questions about equitable access to any future interventions. Will these technologies be affordable and accessible to all, or will they exacerbate existing health disparities? The program’s success hinges on multidisciplinary collaboration, and the call for diverse teams is a positive step, but ensuring genuine inclusivity and representation will be crucial.
The next steps for STOMP involve soliciting proposals from research teams and establishing a clear timeline for deliverables. The program’s long-term impact will depend not only on the scientific breakthroughs achieved but also on how effectively those findings are translated into policy and practice. A key question to watch for in the coming years is whether the data generated by STOMP will lead to meaningful changes in plastic production and usage, or whether it will simply provide a more detailed understanding of a problem that remains largely unaddressed. Specifically, will the risk stratification mechanism influence regulatory decisions regarding plastic additives and manufacturing processes, and will it empower consumers to make more informed choices about the products they use? The answers to these questions will determine whether STOMP truly illuminates the path toward a healthier future, or merely shines a light on the scale of the challenge.
